NEXGEL, Inc. (NXGL)
USD 4.23
(-10.19%)
USD 4.23
(-10.19%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 513 Thousand USD | -72.43% |
| 2022 | 1.86 Million USD | -7.41% |
| 2021 | 2.01 Million USD | 135.36% |
| 2020 | 854 Thousand USD | 20.28% |
| 2019 | 710 Thousand USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 645 Thousand USD | -2.71% |
| 2024 Q1 | 663 Thousand USD | 29.24% |
| 2023 Q4 | 513 Thousand USD | -74.95% |
| 2023 FY | 513 Thousand USD | -72.43% |
| 2023 Q3 | 2.04 Million USD | -1.73% |
| 2023 Q1 | 2.13 Million USD | 14.45% |
| 2023 Q2 | 2.08 Million USD | -2.16% |
| 2022 Q2 | 1.93 Million USD | -2.03% |
| 2022 Q3 | 1.9 Million USD | -1.6% |
| 2022 Q1 | 1.97 Million USD | -1.89% |
| 2022 FY | 1.86 Million USD | -7.41% |
| 2022 Q4 | 1.86 Million USD | -2.1% |
| 2021 Q4 | 2.01 Million USD | -1.86% |
| 2021 FY | 2.01 Million USD | 135.36% |
| 2021 Q3 | 2.04 Million USD | 709.49% |
| 2021 Q2 | 253 Thousand USD | -69.3% |
| 2021 Q1 | 824 Thousand USD | -3.51% |
| 2020 Q2 | 915 Thousand USD | 33.97% |
| 2020 Q1 | 683 Thousand USD | -3.8% |
| 2020 FY | 854 Thousand USD | 20.28% |
| 2020 Q4 | 854 Thousand USD | -4.15% |
| 2020 Q3 | 891 Thousand USD | -2.62% |
| 2019 Q4 | 710 Thousand USD | -3.53% |
| 2019 Q3 | 736 Thousand USD | -4.29% |
| 2019 FY | 710 Thousand USD | 0.0% |
| 2019 Q2 | 769 Thousand USD | -23.18% |
| 2019 Q1 | 1 Million USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 75.25 Million USD | 99.318% |
| AngioDynamics, Inc. | 3.93 Million USD | 86.976% |
| AtriCure, Inc. | 60.59 Million USD | 99.153% |
| Avinger, Inc. | - USD | -Infinity% |
| Azenta, Inc. | 60.43 Million USD | 99.151% |
| BioLife Solutions, Inc. | 18.31 Million USD | 97.198% |
| The Cooper Companies, Inc. | 2.52 Billion USD | 99.98% |
| Daxor Corporation | 755.65 Thousand USD | 32.112% |
| Ekso Bionics Holdings, Inc. | 4.83 Million USD | 89.383% |
| Femasys Inc. | 4.25 Million USD | 87.953% |
| GlucoTrack, Inc. | 196 Thousand USD | -161.735% |
| Harvard Bioscience, Inc. | 30.7 Million USD | 98.329% |
| Hologic, Inc. | 2.49 Billion USD | 99.979% |
| ICU Medical, Inc. | 1.57 Billion USD | 99.967% |
| Intuitive Surgical, Inc. | -82.1 Million USD | 100.625% |
| KORU Medical Systems, Inc. | 3.65 Million USD | 85.956% |
| LeMaitre Vascular, Inc. | 16.62 Million USD | 96.914% |
| Innovative Eyewear, Inc. | - USD | -Infinity% |
| Innovative Eyewear, Inc. | - USD | -Infinity% |
| Masimo Corporation | 871.7 Million USD | 99.941% |
| Microbot Medical Inc. | 40 Thousand USD | -1182.5% |
| Meihua International Medical Technologies Co., Ltd. | 4592.00 USD | -11071.603% |
| Merit Medical Systems, Inc. | 823.01 Million USD | 99.938% |
| Nephros, Inc. | 1.39 Million USD | 63.094% |
| NovoCure Limited | 596.24 Million USD | 99.914% |
| NEXGEL, Inc. | 513 Thousand USD | 0.0% |
| Singular Genomics Systems, Inc. | 67.52 Million USD | 99.24% |
| OraSure Technologies, Inc. | 11.38 Million USD | 95.495% |
| Pro-Dex, Inc. | 7.53 Million USD | 93.193% |
| Pulse Biosciences, Inc. | 8.08 Million USD | 93.656% |
| Predictive Oncology Inc. | 2.18 Million USD | 76.564% |
| Precision Optics Corporation, Inc. | 1.93 Million USD | 73.529% |
| QuidelOrtho Corporation | 2.27 Billion USD | 99.977% |
| Repligen Corporation | 510.14 Million USD | 99.899% |
| Sanara MedTech Inc. | 9.11 Million USD | 94.371% |
| STAAR Surgical Company | 31.46 Million USD | 98.37% |
| Sharps Technology, Inc. | - USD | -Infinity% |
| Utah Medical Products, Inc. | 295 Thousand USD | -73.898% |
| DENTSPLY SIRONA Inc. | 1.79 Billion USD | 99.971% |
| Jin Medical International Ltd. | - USD | -Infinity% |